TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Combined AUC for Selected Patient Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in s-FMDRS score post exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life in inflammatory bowel disease
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in clinical signs and symptoms associated with blepharitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction regarding management of ED
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Angiographic presentation of coronary artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Symptomatic presentation of coronary artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radiation dose to the operator at the chest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation dose to the operator at the forearm level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in VH assessed by oxygen-enhanced 1H MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in VH assessed by 19F-perfluoropropane MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in VH assessed by Lung Clearance Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in VH assessed by Conducting Airway Heterogeneity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in VH assessed by Forced Expiratory Volume in 1 second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: cell-free and exosomal-miRNA biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food Allergy Symptom Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical preparedness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of fracture restoration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of restoration with retention loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Success rate of bronchoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total duration of hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Resolution of Primary Injected Wart(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Neuro-immunological effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of patient falls
Endpoint domain: Adverse events/effects
Primary endpoint: Stair Climb test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale: Pain
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Coagulation screen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Thrombophilia screen
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: VWF, FVIII
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants with Adverse Events by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline in Respiratory Rate Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline in Oxygen Saturation Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline in Pulse Rate Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in Systolic Blood Pressure Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in plasma levels of motilin, ghrelin, somatostatin, GLP-1 and CCK
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Difference in DRSP scale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: COX-II expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mortality rate at hospital discharge
Endpoint domain: Mortality/survival
Primary endpoint: Change in Pain From Baseline to IUD Insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure at Week 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Incidence of peri- and postoperative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number and severity of treatment-emergent adverse events (TEAEs) of nausea and/or vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma levels of noradrenaline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Time to RBC transfusion dependence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Success rate of breastfeeding
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Experiencing Clinically Significant Changes in Laboratory Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Clinically Significant Changes in Electrocardiogram (ECG) Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of persisting pockets >4 mm bleeding upon probing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sino-Nasal Outcome Test (SNOT) 22 Total Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Kinematic movement characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Serum Insulin Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Maximum Serum Insulin Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area Under the Serum Concentration-Time Curve (AUC[0-t'])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Proportion of surgical patients receiving EN and/or PN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Savings and Asset Accumulation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Reduction of HPV DNA positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Overall Target Plaque Severity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Potentially Clinically Significant (PCS) Laboratory Abnormalities Reported as TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Breathing regulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Risk perception of pregnancy risk
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: The incidence of cardiac complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression of chronic renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Lesions detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum cholinesterase activity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persisting Effects Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hood Mysticism Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: States of Consciousness Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: fMRI Resting State Functional Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in alcohol craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in attentional bias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in alcohol interference
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in approach-avoidance tendencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical performance of needles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: radiographic-progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Objective response (CR+PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: total bacterial count (TBC) per mL of milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean dietary adequacy of protein, Ca, and vitamin B12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attention and processing speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preoperatory levels of CA 19.9
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Daily Life Activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Composite of ischemic stroke, hemorrhagic stroke and systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Reduction of Intraocular Pressure (IOP) by 15% or Documentation of a Plan of Care
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of pelvic floor muscle strength abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: PK parameters (Cmax and AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: response rate at end of placebo-controlled phase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of TWA test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional modulation of motor response time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional memory performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percentage of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced Treatment Emergent Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Experienced Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects Who Died
Endpoint domain: Mortality/survival
Primary endpoint: Number of Subjects Who Had Respiratory Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUC0-inf [Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t [Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute 11C-PBR28 binding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of prescription of anti-osteoporosis treatments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: (β-hCG) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of patients presenting hepatitis B virus reactivation
Endpoint domain: Adverse events/effects
Primary endpoint: IIEF-ED Domain score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in ERC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CDRS-R
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diarrhea %
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ferritin (mcg/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Treatment-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Accuracy of non-invasive hemoglobin measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Precision of non-invasive hemoglobin measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Self-reported reactivity to cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lab-based reactivity to cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distinction between CADASIL subjects with and without migraine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Serological assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of ejection fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Wound healing measured by visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of Acute Myocardial Infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Resolution of bile leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of cholangitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Participants With 7 Days Observation Without Severe Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Number of DOAC-Related Clinically Important Medication Errors
Endpoint domain: Adverse events/effects
Primary endpoint: Alleviated stress 1 - short term
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Alleviated stress 2 - short term
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Alleviated stress 3 - short term
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Entry of f-URS into the low kidney calyx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Normal tissue toxicities (Acute & Late)
Endpoint domain: Adverse events/effects
Primary endpoint: treatment-emergent cough
Endpoint domain: Adverse events/effects
Primary endpoint: new wheezes or crackles
Endpoint domain: Adverse events/effects
Primary endpoint: 24h melatonin and cortisol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: change in retinal sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Productivity (correct output per hour)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Troponin I change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With a Static Physician Global Assessment (sPGA) of (0,1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) ≥75% (PASI75) Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of mortality
Endpoint domain: Mortality/survival
Primary endpoint: Post-operative ileus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent of sputum neutrophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neutrophil-lymphocyte count ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Transcriptomic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metabolomic changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Delirium status during hospital stay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Delirium status at 1 month after discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Delirium status at 3 months after discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in 10-Item Perceived Stress Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in 15-Item Mindful Attention Awareness Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Maximum Plasma Concentration (Cmax) of Total and Free Dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve up to the Last Quantifiable Concentration (AUClast) of Total and Free Dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve up to Infinity (AUCinf) of Total and Free Dabigatran
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral Load measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CD4/CD8 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Recurrence after complete remission
Endpoint domain: Mortality/survival
Primary endpoint: Antiviral activity of VCH-222
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety and tolerability of VCH-222
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with true resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Response Rate to lenalidomide (CR, PR and unconfirmed complete responses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: cfDNA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IL-6 mRNA expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Activation of NF-κB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Manual Muscle Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability]
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Duration (in Minutes) of Recovery From Dialysis Treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cutaneous perception threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-month MACE
Endpoint domain: Mortality/survival
Primary endpoint: Chemotherapy induced fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in total score of K-BILD questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Bayley Scales of Infant and Toddler Development (BSID-III) scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum Glucose Infusion Rate (GIR) to maintain euglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Worst measure of disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Concentration-time Curve (AUC0-t) Atorvastatin Acid (Lomitapide 10 mg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under Concentration-time Curve (AUC0-t) Simvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under Concentration-time Curve (AUC0-t) Total Ezetimibe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under Concentration-time Curve (AUC0-t) Rosuvastatin (Lomitapide 10 mg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline gait parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of postoperative nutrition complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of postoperative immune-related complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes